Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment
ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (...
में बचाया:
| मुख्य लेखकों: | , , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
2023
|
| ऑनलाइन पहुंच: | https://doi.org/10.2217/fon-2022-1196 |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|